
Douglas G Ward

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3510079/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of serum biomarkers for colon cancer by proteomic analysis. British Journal of Cancer, 2006, 94, 1898-1905.	2.9	198
2	Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica, 2009, 94, 1748-1752.	1.7	161
3	An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nature Communications, 2021, 12, 2301.	5.8	159
4	Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA. European Journal of Human Genetics, 2016, 24, 1167-1174.	1.4	115
5	Increased hepcidin expression in colorectal carcinogenesis. World Journal of Gastroenterology, 2008, 14, 1339.	1.4	87
6	Liver Tumors in Wild Flatfish: A Histopathological, Proteomic, and Metabolomic Study. OMICS A Journal of Integrative Biology, 2005, 9, 281-299.	1.0	82
7	A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer. Bladder Cancer, 2016, 2, 301-317.	0.2	79
8	Familial dilated cardiomyopathy mutations uncouple troponin I phosphorylation from changes in myofibrillar Ca2+ sensitivity. Cardiovascular Research, 2013, 99, 65-73.	1.8	68
9	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLoS ONE, 2016, 11, e0149756.	1.1	66
10	Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. British Journal of Cancer, 2006, 94, 287-292.	2.9	62
11	SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard. Proteome Science, 2008, 6, 28.	0.7	60
12	Proteomic profiling of urine for the detection of colon cancer. Proteome Science, 2008, 6, 19.	0.7	56
13	The effect of carbohydrate ingestion on plasma interleukin-6, hepcidin and iron concentrations following prolonged exercise. Cytokine, 2011, 53, 196-200.	1.4	51
14	Mutations in troponin T associated with Hypertrophic Cardiomyopathy increase Ca2+-sensitivity and suppress the modulation of Ca2+-sensitivity by troponin I phosphorylation. Archives of Biochemistry and Biophysics, 2016, 601, 113-120.	1.4	49
15	Targeted deep sequencing of urothelial bladder cancers and associated urinary <scp>DNA</scp> : a 23â€gene panel with utility for nonâ€invasive diagnosis and risk stratification. BJU International, 2019, 124, 532-544.	1.3	47
16	Functional Analysis of a Unique Troponin C Mutation, GLY159ASP, that Causes Familial Dilated Cardiomyopathy, Studied in Explanted Heart Muscle. Circulation: Heart Failure, 2009, 2, 456-464.	1.6	46
17	Identification of macrophage migration inhibitory factor and human neutrophil peptides 1–3 as potential biomarkers for gastric cancer. British Journal of Cancer, 2009, 101, 295-302.	2.9	45
18	Structural Basis of Ligand Interactions of the Large Extracellular Domain of Tetraspanin CD81. Journal of Virology, 2012, 86, 9606-9616.	1.5	42

DOUGLAS G WARD

#	Article	IF	CITATIONS
19	Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma. British Journal of Cancer, 2013, 108, 1854-1861.	2.9	41
20	Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. European Journal of Cancer, 2013, 49, 2214-2222.	1.3	41
21	Toward Personalised Liquid Biopsies for Urothelial Carcinoma: Characterisation of ddPCR and Urinary cfDNA for the Detection of the TERT 228 G>A/T Mutation. Bladder Cancer, 2018, 4, 41-48.	0.2	40
22	Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM. British Journal of Cancer, 2015, 112, 1052-1058.	2.9	36
23	Characterization of the transition-metal-binding properties of hepcidin. Biochemical Journal, 2010, 427, 289-296.	1.7	35
24	Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential. British Journal of Cancer, 2014, 110, 679-685.	2.9	35
25	Myofibrillar Ca2+ sensitivity is uncoupled from troponin I phosphorylation in hypertrophic obstructive cardiomyopathy due to abnormal troponin T. Cardiovascular Research, 2013, 97, 500-508.	1.8	34
26	Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood Cells, Molecules, and Diseases, 2012, 48, 233-237.	0.6	33
27	Liquid biopsies for bladder cancer. Translational Andrology and Urology, 2017, 6, 331-335.	0.6	33
28	Characterization of the Interaction between the N-Terminal Extension of Human Cardiac Troponin I and Troponin Câ€. Biochemistry, 2004, 43, 4020-4027.	1.2	32
29	Robust twin boosting for feature selection from high-dimensional omics data with label noise. Information Sciences, 2015, 291, 1-18.	4.0	32
30	Binding of 2′(3′)-O-(2,4,6-Trinitrophenyl)ADP to Soluble αβ Protomers of Na,K-ATPase Modified with Fluorescein Isothiocyanate. Journal of Biological Chemistry, 1996, 271, 12317-12321.	1.6	30
31	Plasma Proteome Analysis Reveals the Geographical Origin and Liver Tumor Status of Dab (Limanda) Tj ETQq1 1	0.784314 4.6	∔rgǥŢ /Overioα
32	NMR and Mutagenesis Studies on the Phosphorylation Region of Human Cardiac Troponin I. Biochemistry, 2004, 43, 5772-5781.	1.2	29
33	Assessment of highâ€throughput highâ€resolution MALDIâ€TOFâ€MS of urinary peptides for the detection of muscleâ€invasive bladder cancer. Proteomics - Clinical Applications, 2011, 5, 493-503.	0.8	29
34	A Cross-Linking Study of the N-Terminal Extension of Human Cardiac Troponin Iâ€. Biochemistry, 2003, 42, 10324-10332.	1.2	28
35	Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. Scientific Reports, 2018, 8, 11290.	1.6	28
36	Preclinical and post-treatment changes in the HCC-associated serum proteome. British Journal of Cancer, 2006, 95, 1379-1383.	2.9	27

Douglas G Ward

#	Article	IF	CITATIONS
37	Structural Consequences of Cardiac Troponin I Phosphorylation. Journal of Biological Chemistry, 2002, 277, 41795-41801.	1.6	26
38	Tropomyosin isoform expression and phosphorylation in the human heart in health and disease. Journal of Muscle Research and Cell Motility, 2013, 34, 189-197.	0.9	25
39	Globotriaosylsphingosine (Lysoâ€Gb ₃) as a biomarker for cardiac variant (N215S) Fabry disease. Journal of Inherited Metabolic Disease, 2018, 41, 239-247.	1.7	25
40	The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM. Journal of General Physiology, 2019, 151, 18-29.	0.9	25
41	The Importance of the Carboxyl-terminal Domain of Cardiac Troponin C in Ca2+-sensitive Muscle Regulation. Journal of Biological Chemistry, 2000, 275, 32508-32515.	1.6	23
42	Assessment of novel combinations of biomarkers for the detection of colorectal cancer. Cancer Biomarkers, 2011, 7, 123-132.	0.8	23
43	Estimation of polyclonal Ig <scp>G</scp> 4 hybrids in normal human serum. Immunology, 2014, 142, 406-413.	2.0	23
44	Affinity Labeling of Two Nucleotide Sites on Na,K-ATPase Using 2′(3′)-O-(2,4,6-Trinitrophenyl)8-azidoadenosine 5′-[α-32P]Diphosphate (TNP-8N3-[α-32P]ADP) as a Photoactivatable Probe. Journal of Biological Chemistry, 1998, 273, 33759-33765.	1.6	19
45	Additional PKA phosphorylation sites in human cardiac troponin I. FEBS Journal, 2001, 268, 179-185.	0.2	18
46	Photoinactivation of Fluorescein Isothiocyanate-modified Na,K-ATPase by 2′(3′)-O-(2,4,6-Trinitrophenyl)8-azidoadenosine 5′-Diphosphate. Journal of Biological Chemistry, 1998, 2 14277-14284.	7 3 ,6	17
47	Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis. European Journal of Cancer, 2021, 158, 191-207.	1.3	17
48	MALDI profiles of proteins and lipids for the rapid characterisation of upper GI-tract cancers. Journal of Proteomics, 2013, 80, 207-215.	1.2	15
49	Macrophage migration inhibitory factor and DJ-1 in gastric cancer: differences between high-incidence and low-incidence areas. British Journal of Cancer, 2012, 107, 1595-1601.	2.9	14
50	Proteomic profiling of <scp>N</scp> â€linked glycoproteins identifies <scp>C</scp> on <scp>A</scp> â€binding procathepsin <scp>D</scp> as a novel serum biomarker for hepatocellular carcinoma. Proteomics, 2014, 14, 186-195.	1.3	14
51	Is iron overload in alcohol-related cirrhosis mediated byhepcidin?. World Journal of Gastroenterology, 2009, 15, 5864.	1.4	14
52	Analysis of premalignant pancreatic cancer mass spectrometry data for biomarker selection using a group search optimizer. Transactions of the Institute of Measurement and Control, 2012, 34, 668-676.	1.1	13
53	Oral Iron Treatment Response and Predictors in Anaemic Adolescents and Adults with IBD: A Prospective Controlled Open-Label Trial. Journal of Crohn's and Colitis, 2016, 11, jjw208.	0.6	13
54	Z-band Alternatively Spliced PDZ Motif Protein (ZASP) Is the Major O-Linked β-N-Acetylglucosamine-substituted Protein in Human Heart Myofibrils. Journal of Biological Chemistry, 2013, 288, 4891-4898.	1.6	12

DOUGLAS G WARD

#	Article	IF	CITATIONS
55	Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA. European Urology Oncology, 2023, 6, 67-75.	2.6	12
56	Back-Splicing Transcript Isoforms (Circular RNAs) Affect Biologically Relevant Pathways and Offer an Additional Layer of Information to Stratify NMIBC Patients. Frontiers in Oncology, 2020, 10, 812.	1.3	11
57	Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. Journal of Nephrology, 2015, 28, 81-88.	0.9	10
58	Metabolomic Evidence for a Field Effect in Histologically Normal and Metaplastic Tissues in Patients with Esophageal Adenocarcinoma. Neoplasia, 2017, 19, 165-174.	2.3	10
59	Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. Bladder Cancer, 2019, 5, 263-272.	0.2	10
60	The Sirenic Links between Diabetes, Obesity, and Bladder Cancer. International Journal of Molecular Sciences, 2021, 22, 11150.	1.8	10
61	Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma. British Journal of Cancer, 2014, 110, 2277-2282.	2.9	9
62	Structural investigation of hemicelluloses from <i>Plantago ovata</i> , <i>Mimosa pudica</i> and <i>Lallemantia royleana</i> by MALDI-ToF mass spectrometry. Journal of Carbohydrate Chemistry, 2018, 37, 285-301.	0.4	9
63	Calcium and Peptide Binding to Folded and Unfolded Conformations of Cardiac Troponin C. Electrospray Ionization and Fourier Transform Ion Cyclotron Resonance Mass Spectrometry. European Journal of Mass Spectrometry, 2002, 8, 471-481.	0.5	7
64	Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen. European Journal of Gastroenterology and Hepatology, 2010, 22, 1358-1363.	0.8	7
65	A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients. Journal of the American Society for Mass Spectrometry, 2016, 27, 719-725.	1.2	7
66	Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer. International Journal of Molecular Sciences, 2019, 20, 1102.	1.8	7
67	Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?. Translational Andrology and Urology, 2021, 10, 2787-2808.	0.6	7
68	Inactivation of Na,K-ATPase Following Co(NH3)4ATP Binding at a Low Affinity Site in the Protomeric Enzyme Unit. Journal of Biological Chemistry, 2003, 278, 14688-14697.	1.6	6
69	10 Years of SELDI: What Have we Learnt?. Current Proteomics, 2010, 7, 15-25.	0.1	6
70	Integrative topological analysis of mass spectrometry data reveals molecular features with clinical relevance in esophageal squamous cell carcinoma. Scientific Reports, 2016, 6, 21586.	1.6	6
71	A potential role for hepcidin in obesity-driven colorectal tumourigenesis. Oncology Reports, 2018, 39, 392-400.	1.2	6
72	Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer. Proteomes, 2015, 3, 266-282.	1.7	5

DOUGLAS G WARD

#	Article	IF	CITATIONS
73	Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes. Genome Medicine, 2022, 14, .	3.6	5
74	TNP-8N3-ADP Photoaffinity Labeling of Two Na,K-ATPase Sequences under Separate Na+ plus K+ Control. Biochemistry, 2006, 45, 3460-3471.	1.2	4
75	Urine DNA for monitoring chemoradiotherapy response in muscleâ€invasive bladder cancer: a pilot study. BJU International, 2021, , .	1.3	3
76	STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes. European Urology Open Science, 2022, 38, 88-95.	0.2	3
77	Confounding Effects of Benign Lung Diseases on Non-Small Cell Lung Cancer Serum Biomarker Discovery. Clinical Proteomics, 2009, 5, 148-155.	1.1	2
78	Proteomic analysis of resectable non-small cell lung cancer: post-resection serum samples may be useful in identifying potential markers. Interactive Cardiovascular and Thoracic Surgery, 2011, 13, 3-6.	0.5	2
79	Irreversible effects of calcium ions on the plasma membrane calcium pump. Journal of Membrane Biology, 1993, 136, 313-26.	1.0	0
80	K+Induces an Acid-Labile Phosphoenzyme (or an Occluded PiForm) in Na,K-ATPase. Annals of the New York Academy of Sciences, 1997, 834, 381-385.	1.8	0
81	Nucleotides Trigger the Release of Co(NH3)4ATP Tightly Bound to Inactivated Na,K-ATPase. Annals of the New York Academy of Sciences, 1997, 834, 432-434.	1.8	Ο